The bioactivity of plant extracts against representative bacterial pathogens of the lower respiratory tract
© Camacho-Corona et al; licensee BioMed Central Ltd. 2009
Received: 27 January 2009
Accepted: 01 June 2009
Published: 01 June 2009
Lower respiratory tract infections are a major cause of illness and death. Such infections are common in intensive care units (ICU) and their lethality persists despite advances in diagnosis, treatment and prevention. In Mexico, some plants are used in traditional medicine to treat respiratory diseases or ailments such as cough, bronchitis, tuberculosis and other infections. Medical knowledge derived from traditional societies has motivated searches for new bioactive molecules derived from plants that show potent activity against bacterial pathogens. Therefore, the aim of this study was to evaluate the effect of hexanic, chloroformic (CLO), methanolic (MET) and aqueous extracts from various plants used in Mexican traditional medicine on various microorganisms associated with respiratory disease.
thirty-five extracts prepared from nine plants used in Mexican traditional medicine for the treatment of respiratory infections were evaluated against 15 control bacterial species and clinical isolates.
Both chloroformic (CLO) and methanolic (MET) extracts of Larrea tridentata were active against Methicillin-resistant S. aureus, B. subtilis and L. monocytogenes. A MET extract of L. tridentata was also active against S. aureus, S. pneumoniae, S. maltophilia, E. faecalis and H. influenzae and the CLO extract was active against A. baumannii. An Aqueous extract of M. acumitata and a MET extract of N. officinale were active against S. pneumoniae. CLO and MET extracts of L. tridentata were active against clinical isolates of S. aureus, S. pneumoniae and E. faecalis.
Overall, our results support the potential use of L. tridentata as a source of antibacterial compounds.
Lower respiratory tract infections are a major cause of illness and death and are common in intensive care units (ICU) [1, 2]. The most frequent causal agents of these infections are Streptococcus pneumoniae, Klebsiella pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Pseudomonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia. Some additional and less frequent causative agents are Escherichia coli, Enterobacter cloacae, Bacillus subtilis , Bacillus cereus , Listeria monocytogenes , and Enterococcus faecalis .
Infections with these bacteria are associated with high morbidity and mortality, especially in immunocompromised patients [7–10]. Methicillin-resistant S. aureus (MRSA) is of particular concern in the United States since approximately 60% of all staphylococcal infections in the ICU are caused by MRSA [11, 12]. Penicillin-resistant S. pneumoniae and vancomycin-resistant enterococci are an additional cause for concern in the clinical setting .
In Mexico, some plants are used in traditional medicine to treat respiratory diseases or ailments such as cough, bronchitis, tuberculosis and other infections [14, 15]. The known success of these traditional therapies has guided the search for new chemotherapeutic alternatives to fight respiratory and other infections caused by drug-resistant bacteria [16–18]. Therefore, the aim of this study was to evaluate the effect of hexanic, chloroformic (CLO), methanolic (MET) and aqueous extracts from various plants used in Mexican traditional medicine on various microorganisms associated with respiratory disease.
Plant material and preparation of extracts
We reviewed Mexican ethnobotanical literature and selected a group of plants used by traditional healers to treat respiratory infections [14, 15]. In 2004, nine plants were collected by the biologist Mauricio Gonzalez-Ferrara from different states of Mexico, and authenticated by the Biologist Marcela González-Alvarez. Voucher specimens were deposited at the UANL herbarium located in the Facultad de Ciencias Biológicas of the Universidad Autonoma de Nuevo Leon, Mexico.
Plant names, author of the name, plant family, parts used, voucher number, and the state where collected were as follows: Citrus aurantifolia (Christm) Swingle (Rutaceae), fruit peel, 024769, Nuevo Leon; Citrus sinensis (L) Osbeck (Rutaceae), fruit peel, 024770, Nuevo Leon; Foeniculum vulgare P. Mill (Umbelliferae), aerial parts, 024771, Chihuahua; Larrea tridentata (Sessé & Moc. ex. DC) Coville (Zygophyllaceae), aerial parts, 024772, Nuevo Leon; Nasturtium officinale R. Br. (Cruciferae), aerial parts, 024774, Nuevo Leon; Olea europaea L (Oleaceae), leaves, 024775, Nuevo Leon; Mentha pulegium L. (Labiatae), leaves, 024777, purchased in the Sonora Market in Mexico City; Rosa centifolia L. (Rosaceae), petals, 024776, Morelos and Musa acuminata Colla (Musaceae), stems, 024773, Guerrero.
Approximately 50 g of dried and ground plant material was successively extracted by maceration with hexane, chloroform, methanol and water. Organic extracts were concentrated in vacuo to dryness, and aqueous extracts were freeze-dried. All extracts were stored at 4°C until use.
Hexanic, CLO, MET and aqueous extracts were made from the following: C. aurantifolia, C. sinensis, F. vulgare, L. tridentata, N. officinale, O. europaea, M. pulegium, R. centifolia. Only CLO, MET and aqueous extracts were prepared form M. acuminata because of limited plant material availability.
Stock solutions were prepared from extracts at a concentration of 20 mg/ml. For organic extracts, DMSO was used as a solvent. Aqueous extracts were prepared in distilled water and sterilized by filtration through a 0.22 μm membrane.
Bacterial strains and preparation of inocula
Two sets of control species or phenotypic groups of bacteria were tested. The Gram-negative bacteria were S. maltophilia ATCC 12714, E. coli ATCC 25922, A. baumannii ATCC 15308, H. influenzae ATCC 49766, H. influenzae ATCC 49247, P. aeruginosa ATCC 27853, K. pneumoniae ATCC 700603 and E. cloacae ATCC 35030. The Gram-positive strains were: S. aureus ATCC 29213, S. aureus MRSA ATCC BAA-44, B. subtilis ATCC 6633, B. cereus ATCC 49064, S. pneumoniae ATCC 49619, L. monocytogenes ATCC 19111 and E. faecalis ATCC 29212.
Before testing, strains were inoculated onto plates prepared with 5% blood agar and cultured overnight at 37°C. For H. influenzae, strains were inoculated onto chocolate agar and incubated in a 5% CO2 atmosphere for 48 h. Turbidity was adjusted to 0.5 of the McFarland standard to prepare the test inoculum. Afterwards, 10 μl were transferred into 11 ml Mueller Hinton broth to achieve 5 × 105 CFU/ml. HTM medium was used for H. influenzae and Mueller Hinton with TES/lysed horse blood was used for S. pneumoniae.
Screening of antimicrobial activity and reference drugs
Minimal inhibitory concentration (MIC) for each extract was determined for both Gram-negative and Gram-positive bacteria by the microdilution method  with dilutions ranging from 250 to 7.8 μg/ml. Extracts that caused complete inhibition of growth at 24 h were considered active and used for the subsequent assays. All assays were performed in duplicate.
Two extracts with the broadest spectrum of activity were further tested against clinical isolates of susceptible species collected at the Hospital Universitario "Dr. José Eleuterio" Gonzalez and deposited at the Microbiology Department, School of Medicine, UANL. These isolates included A. baumannii (n = 25), E. faecalis (n = 15), S. aureus (n = 25), and S. pneumoniae (n = 13; total n = 78). H. influenzae was not included because clinical isolates were not available.
For all assays, adequate media without drug or extract was used as control.
As a reference for the screening assays, MICs for the antimicrobial drugs ceftazidime (Caz), ciprofloxacin, levofloxacin (Lv) and vancomycin (Va) were determined by the broth microdilution method recommended by the Clinical and Laboratory Standards Institute . As a reference for the assays with clinical isolates, we evaluated the susceptibility pattern for each clinical isolate against the following commonly used antibiotics: Caz, Lv, Va, minocycline, penicillin, piperacillin tazobactam, amoxicillin clavulanic acid, ampicillin, linezolid, meropenem, amikacin, cefepime, and/or ceftriaxone.
CLO and MET extracts of L. tridentata, MET extract of N. officinale and aqueous extract of M. acuminata were all active against several Gram-positive bacteria and Gram-negative bacteria [see Additional file 1]. None of the 35 extracts were active against B. cereus, E. coli, P. aeruginosa, K. pneumoniae or E. cloacae strains at the tested concentrations. Hexanic, CLO, MET and aqueous extracts of C. aurantiifolia, C. sinensis, F. vulgare, M. pulegium, O. europaea and R. centifolia did not show activity against any of the 15 bacteria of phenotypic groups.
We selected the CLO and MET extracts of L. tridentata because of their broad bioactivity and evaluated their effects on clinical isolates of species that showed sensitivity to these extracts. The clinical isolates included were A. baumannii (n = 25), E. faecalis (n = 15), S. pneumoniae (n = 13) and S. aureus (n = 25). The most potent antibacterial activity occurred against the S. pneumoniae strains [see Additional file 2] with MIC50 and MIC80 values of 31.25 μg/ml for both CLO and MET extracts, respectively. These extracts also showed potent activity against E. faecalis (n = 15, MIC50 = 250 μg/ml for both extracts) and S. aureus (n = 25, MIC80 = 125 μg/ml for both extracts) [see Additional file 2]. No activity was detected against any clinical isolates of A. baumannii (n = 25).
Discussion and conclusion
Among the plant extracts that showed antibacterial activity, the CLO and MET extracts of L. tridentata showed the broadest and most promising spectrum of activity. In order to confirm this activity, we tested those extracts against clinical isolates of species that showed sensitivity to these extracts in the screening assay.
Both extracts confirmed the antibacterial activity, not only in control strains, but also against strains isolated from patient's clinical samples. The best activity was observed against S. pneumoniae (MICs80 = 31.25 μg/ml). When tested against S. pneumoniae, the antimicrobial activity of CLO and MET extracts of L. tridentata were comparable to the activity observed for reference antimicrobial drugs. It is possible that further isolation of the active compound(s) will render lower MIC values.
Both the CLO and MET extracts of L. tridentata also showed good activity against E. faecalis (MICs50 = 250 μg/ml) and S. aureus (MICs80= 125 μg/ml). These results are quite interesting, given the high drug-resistance observed for those clinical isolates. The CLO and MET extracts of L. tridentata were active against MDR clones of S. aureus. These results are particularly important because of the increase in morbidity and mortality related to clones of MDR S. aureus in the last two decades .
No activity was detected against any clinical isolates of A. baumannii. Nevertheless, this is not a surprising result sinceclinical isolates of A. baumannii show a strong drug-resistance, so there are likely multiple antimicrobial-resistance mechanisms in these strains.
The CLO and MET extracts of L. tridentata showed different activity spectra. Verastegui et al. reported that ethanolic extract of L. tridentata was active against L. monocytogenes, Clostridium perfringens, Shigella dysenteriae, Yersinia enterocolitica and Proteus vulgaris, with a MIC ranging from 10 to 19 μg/ml, yet they did not find activity against E. coli . We found that CLO and MET extracts of L. tridentata showed activity against L. monocytogenes and no activity against E. coli. This confirms the antibiotic activity of L. tridentata extracts; however, it is difficult to compare our results directly with Verastegui et al. because we did not include these ethanolic extracts in our study.
L. tridentata (Creosote bush) is an abundant plant of Mexican and US-American deserts. The potent antioxidant nordihydroguaiaretic acid (NDGA) has been identified from this plant . This lignan is a potential therapeutic molecule for Sjorgren-Larsson syndrome, cardiopathies, skin cancer prevention, and viral infections . We presume that the compounds present in our L. tridentata CLO extract are not NDGA because they have a different polarity. Thus, they are potentially novel antibacterial molecules. Antimicrobial properties for some plant species tested in the study have previously been described but not with a special focus on respiratory tract pathogens and the inclusion of some bacterial MDR clones.
Our results showed that the MET extract of N. officinale and the aqueous extract of M. acuminata were active against S. pneumoniae. N. officinale has been used for the treatment of renal, liver disease , and has also been shown to reduce oxidative stress in hypercholesterolemic rats . This plant has also been shown to have cardio-protective activity  and antimycobacterial potential . Indeed, several antimicrobial compounds have been identified in N. officinale. Specifically, a phenyl-phenalenone has been isolated and evaluated for leishmanicidal activity and isolated phytoalexins are known to have antifungal activity . We found that the methanolic extract of N. officinale is active against S. pneumoniae.
Our results also demonstrated the activity of M. acuminata aqueous extract against S. pneumoniae ATCC 49619 (250 μg/ml). Similarly, activity of M. acuminata MET extract against Mycobacterium tuberculosis has been previously reported . To our knowledge, there is no other antimicrobial activity report for extracts form M acuminata.
Our findings do conflict with some of the previously published results on the same plant extracts. We did not find antibacterial activity in several plants whose antimicrobial effects have been documented. For example, we did not find any antibacterial activity in extract from O. europaea, yet another group isolated the aldehyde hexanal extract from O. europaea and reported bioactivity against multiple types of microorganisms . In addition, a terpenoid extracted from C. sinensis with antifungal activity has been isolated from the fruit peel , yet we found no effect of the extract in our study.
The differences between our study and theirs could have multiple explanations. The strains or clones and the testing concentrations differed and perhaps local environmental factors that affect the potency of medicinal plants, such as temperature, rainfall, day length and soil characteristics may have differed between the plant samples used for each study. Also, it is important to consider differences in the conditions of extract preparation and in the extract concentrations tested.
Our study has provided and confirmed previous evidence that L. tridentata is a promising alternative source for antimicrobial compounds. It is particularly valuable in the context of the bacterial resistance that is prevalent. Our group is currently conducting a study to isolate the active compounds in this extract.
Lastly, the activity observed for L. tridentata provides a rationale for its use in the treatment of respiratory infectious diseases in traditional medicine.
List of abbreviations
Intensive Care Units
Minimal inhibitory concentration.
The authors would like to acknowledge Maria de la Luz Acevedo for her technical assistance.
- Cardoso TC, Lopes LM, Carneiro AH: A case-control study on risk factors for early-onset respiratory tract infection in patients admitted in ICU. BMC Pulm Med. 2007, 7: 12-17. 10.1186/1471-2466-7-12.PubMed CentralView ArticlePubMedGoogle Scholar
- Ibrahim EH, Ward S, Sherman G, Kollef MH: A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest. 2000, 117: 1434-1442. 10.1378/chest.117.5.1434.View ArticlePubMedGoogle Scholar
- Sliman R, Rehm S, Shlaes DM: Serious infections caused by Bacillus species. Medicine (Baltimore). 1987, 66: 218-223.View ArticleGoogle Scholar
- Sue D, Hoffmaster AR, Popovic T, Wilkins PP: Capsule production in Bacillus cereus strains associated with severe pneumonia. J Clin Microbiol. 2006, 44: 3426-3428. 10.1128/JCM.00873-06.PubMed CentralView ArticlePubMedGoogle Scholar
- De Sá FR, Sztajnbok J, De Almeida JF, Troster EJ, Vaz FA: Listeria monocytogenes pneumonia in a cirrhotic child. Int J Clin Pract. 2004, 58: 536-538. 10.1111/j.1368-5031.2004.00122.x.View ArticlePubMedGoogle Scholar
- Bonten MJ, van Tiel FH, Geest van der S, Stobberingh EE, Gaillard CA: Enterococcus faecalis pneumonia complicating topical antimicrobial prophylaxis. N Eng J Med. 1993, 328: 209-210. 10.1056/NEJM199301213280311.View ArticleGoogle Scholar
- Del Toro MD, Rodriguez-Bano J, Martinez-Martinez L, Pascual A, Perez-Canoa R, Perea EJ, Muniain MA: Epidemiology, clinical features and prognosis of infections due to Stenotrophomonas maltophilia. Enferm Infecc Microbiol Clin. 2006, 24: 4-9. 10.1157/13083367.View ArticlePubMedGoogle Scholar
- Kuo LC, Lai CC, Liao CH, Hsu CK, Chang YL, Chang CY, Hsueh PR: Multidrug-resistant Acinetobacter baumannii bacteremia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect. 2007, 13: 196-198. 10.1111/j.1469-0691.2006.01601.x.View ArticlePubMedGoogle Scholar
- Obritsch MD, Fish DN, MacLaren R, Jung R: Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy. 2005, 25: 1353-1364. 10.1592/phco.2005.25.10.1353.View ArticlePubMedGoogle Scholar
- Driscoll JA, Brody SL, Kollef MH: The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs. 2007, 67: 351-368. 10.2165/00003495-200767030-00003.View ArticlePubMedGoogle Scholar
- Ferrara AM: Treatment of hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2007, 30: 19-24. 10.1016/j.ijantimicag.2007.02.011.View ArticlePubMedGoogle Scholar
- Baddour M, Abuelkheri M, Fatani J, Bhol MF, Al-Ahdal MN: Molecular epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) isolates from major hospitals in Riyadh, Saudi Arabia. Ca J Microbiol. 2007, 53: 931-936. 10.1139/W07-063.View ArticleGoogle Scholar
- Berger-Bachi B: Resistance mechanisms of gram-positive bacteria. International J Med Microbiol. 2002, 292: 27-35. 10.1078/1438-4221-00185.View ArticleGoogle Scholar
- Argueta VA, Cano A, Rodarte M: Atlas de las plantas medicinales de la medicina tradicional mexicana. 1994, Tomo I-III. Instituto Nacional Indigenista, México DF, (Spanish).Google Scholar
- Martínez M: Las plantas medicinales de México. 1989, Botas, México DF, (Spanish)., 1Google Scholar
- Davies J: Inactivation of antibiotics and the dissemination of resistance genes. Science. 1994, 264: 375-382. 10.1126/science.8153624.View ArticlePubMedGoogle Scholar
- Hinrich M, Kuhnt M, Wright CW, Rimpler H, Phillipson JD, Schandelmaier A, Warhurst DC: Parasitological and microbiological evaluation of Mixe Indian medicinal plants (Mexico). J Ethnophrmacol. 1992, 36: 81-5. 10.1016/0378-8741(92)90063-W.View ArticleGoogle Scholar
- Giamarellou H: Treatment options for multidrug-resistant bacteria. Expert Rev Anti Infect Ther. 2006, 4: 601-618. 10.1586/1478722.214.171.1241.View ArticlePubMedGoogle Scholar
- Zgoda JR, Porter JR: A convenient microdilution method for screening natural products against bacteria and fungi. Pharm Biol. 2001, 39: 221-225. 10.1076/phbi.126.96.36.19934.View ArticleGoogle Scholar
- National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. 2003, Wayne, PA: NCCLSGoogle Scholar
- Verastegui MA, Sanchez CA, Heredia NL, Garcia-Alvarado JS: Antimicrobial activity of extracts of three major plants from the Chihuahuan desert. J Ethnopharmacol. 1996, 52: 175-177. 10.1016/0378-8741(96)84802-1.View ArticlePubMedGoogle Scholar
- Arteaga S, Andrade-Cetto A, Cárdenas R: Larrea tridentata (Creosote bush), an abundant plant of Mexican and US-American deserts and its metabolite nordihydroguaiaretic acid. J Ethnopharmacol. 2005, 98: 231-239. 10.1016/j.jep.2005.02.002.View ArticlePubMedGoogle Scholar
- Gnabre JN, Brady JN, Clanton DJ, Ito Y, Dittmer J, Bates RB, Huang RC: Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans. Proc Natl Acad Sci USA. 1995, 92: 11239-11243. 10.1073/pnas.92.24.11239.PubMed CentralView ArticlePubMedGoogle Scholar
- Guarrera PM, Salerno G, Caneva G: Folk phytotherapeutical plants from Maratea area (Basilicata, Italy). J Ethnopharmaco. 2005, 99: 367-378. 10.1016/j.jep.2005.01.039.View ArticleGoogle Scholar
- Yazdanparast R, Bahramikia S, Ardestani A: Nasturtium officinale reduces oxidative stress and enhances antioxidant capacity in hypercholesterolaemic rats. Chem Biol Interact. 2008, 172: 176-184. 10.1016/j.cbi.2008.01.006.View ArticlePubMedGoogle Scholar
- Bahramikia S, Yazdanparast R: Effect of hydroalcoholic extracts of Nasturtium officinale leaves on lipid profile in high-fat diet rats. J Ethnopharmacol. 2008, 115: 116-121.View ArticlePubMedGoogle Scholar
- Camacho-Corona M, del R, Ramírez-Cabrera MA, Santiago OG, Garza-González E, Palacios I, de P, Luna-Herrera J: Activity against drug resistant-tuberculosis strains of plants used in Mexican traditional medicine to treat tuberculosis and other respiratory diseases. Phytother Res. 2008, 22: 82-85. 10.1002/ptr.2269.View ArticleGoogle Scholar
- Luque-Ortega JR, Martínez S, Saugar JM, Izquierdo LR, Abad T, Luis JG, et al: Fungus-elicited metabolites from plants as an enriched source for new leishmanicidal agents: antifungal phenyl-phenalenone phytoalexins from the banana plant (Musa acuminata) target mitochondria of Leishmania donovani promastigotes. Antimicrob Agents Chemother. 2004, 48: 1534-1540. 10.1128/AAC.48.5.1534-1540.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Kubo A, Lunde CS, Kubo I: Antimicrobial Activity of the Olive Oil Flavor Compounds. J Agric Food Chem. 1995, 43: 1629-1633. 10.1021/jf00054a040.View ArticleGoogle Scholar
- Stange RR, Midland SL, Eckert JW, Sims JJ: An antifungal compound produced by grapefruit and Valencia orange after wounding of the peel. J Nat Prod. 1993, 56: 1627-1629. 10.1021/np50099a029.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.